- RecruitingPHASE2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study is testing a new medicine called Pirtobrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for people who have already had some treatment for their condition, or for those who haven't had treatment but have a specific gene change.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - RecruitingPHASE4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
This study is for people in the UK who are already taking part in a trial for a cancer medicine called pirtobrutinib. It's looking at how safe and effective the medicine is in the long term for chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
For: Chronic Lymphocytic Leukemia · Non-Hodgkin LymphomaUnited States · Australia · France - Active not recruitingPHASE3
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
For: Lymphoma, Mantle-CellUnited States · Australia · Austria - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with standard treatment (bendamustine and rituximab) for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see which is safer and works better.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - RecruitingPHASE4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study looks at the long-term safety of a medicine called pirtobrutinib for people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It's for those already taking part in a previous pirtobrutinib study, to continue treatment and monitoring.
For: Chronic Lymphocytic Leukemia · Lymphoma, Small LymphocyticUnited States · Australia · Austria - RecruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with ibrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for adults, some of whom may have had previous treatment, and some who are newly diagnosed, especially if they have a specific gene change.
For: Chronic Lymphocytic Leukemia · Leukemia, Lymphocytic · Leukemia, B-cellUnited States · Argentina · Australia - Active not recruitingPHASE3
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study compares a new treatment, Pirtobrutinib, with standard drugs (Venetoclax and Rituximab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who’ve had treatment before. Researchers want to see if the new combination works better and is safe.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
This study is testing a new medicine called pirtobrutinib for people with Immune Thrombocytopenia (ITP). It aims to see how safe it is, what side effects it might cause, and if it helps improve blood platelet counts.
For: Immune Thrombocytopenia (ITP)United States · China · Denmark - RecruitingPHASE4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
This study looks at the long-term safety of a medicine called pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma. It's for people who have already been in other pirtobrutinib studies and want to continue their treatment or follow-up.
For: Chronic Lymphocytic Leukemia · Non-Hodgkin LymphomaUnited States · Australia · France - AuthorisedTherapeutic exploratory (Phase II)
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial
This study looks at a new drug, pirtobrutinib, combined with standard treatment for people with chronic lymphocytic leukaemia (CLL) who haven't had treatment before. Researchers want to see if this combination can get rid of the leukaemia cells effectively and for how long, aiming for a fixed treatment period.
For: Patients with previously untreated symptomatic chronic lymphocytic leukemia.France - AuthorisedTherapeutic exploratory (Phase II)
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
This study looks at a new drug, pirtobrutinib, for older patients with mantle cell lymphoma who might be too unwell for standard treatments. It aims to see how well the drug works to stop the cancer from growing and how safe it is.
For: Mantle Cell LymphomaItaly